ICU sedation, delirium & recovery
Critical care illness in allogeneic hematopoietic stem-cell transplantation recipients with chronic graft versus host disease
Primary result · 90-day mortalityResult — go to the resultHR for 90-day mortality 1.32 95% CI 1.21–1.46Authors' conclusion
In critically ill Allo-HSCT recipients, the presence or severity of cGVHD is not associated with survival and should not influence the decision to admit or not the patient to the ICU.
Study context
- Population
- Critically ill allogeneic hematopoietic stem-cell transplantation (Allo-HSCT) recipients admitted to 14 French intensive care units (ICUs), 2015–2020114 with chronic graft-versus-host disease (cGVHD)
- Participants
- 1,164 participants
- Comparison
- cGVHD vs controlled acute GVHD vs no GVHD
- cGVHDn = 114
- Primary endpoint
- Mortality after admission
- Follow-up
- 90 days
Methodological details14 French ICUs
- 14 French ICUs
Primary result
90-day mortality
HR for 90-day mortality
1.32
95% CI 1.21–1.46
P < 0.01
By group
SOFA score at ICU admission (per point)
HR for 90-day mortality 1.32 (95% CI 1.21–1.46); P < 0.01
Per point, as printed
As reported in the abstract
Further findings
Survival · 3 years
- Prevalence of cGVHD
- 10% · 114
Prevalence of cGVHD
- Severe form in half the patients
cGVHD severity and survival (cGVHD)
- cGVHD severity did not significantly influence survival
Original publication
Critical care illness in allogeneic hematopoietic stem-cell transplantation recipients with chronic graft versus host disease. Crit Care. Published 20 June 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →